Why hypertension needs another treatment option

Hypertension is one of the most important preventable causes of heart attack, stroke, heart failure, chronic kidney disease, and premature death. In the United States, nearly half of adults meet the current definition of hypertension or take medication for it. The challenge is not simply diagnosing the condition; it is achieving reliable, long-term blood pressure control.

Many people need two or more antihypertensive drugs. Some forget doses, struggle with medication costs, or experience side effects such as dizziness, swelling, fatigue, frequent urination, or sexual problems. Others take several medications exactly as prescribed and still have readings above their target.

Understanding resistant hypertension

Resistant hypertension generally means blood pressure remains above goal despite the use of three appropriate medications at maximally tolerated doses, usually including a diuretic. Before applying that label, clinicians must rule out inaccurate measurements, white-coat hypertension, missed doses, interacting medications, and secondary causes such as sleep apnea, kidney disease, renal artery narrowing, or excess production of certain hormones.

This detective work matters. Performing a procedure when the real culprit is an incorrectly sized blood pressure cuff would be rather like replacing the engine because the fuel gauge is broken.

What is renal denervation?

Renal denervation, also called renal artery denervation or RDN, is a catheter-based treatment designed to reduce activity in the sympathetic nerves surrounding the renal arteries. These arteries deliver blood to the kidneys, while the nearby nerves participate in the body’s “fight-or-flight” system.

When these nerves become overactive, they can contribute to blood vessel tightening, sodium retention, hormonal signaling, and increased nervous-system activity throughout the body. The result may be persistently elevated blood pressure. Renal denervation disrupts part of this signaling network without removing a kidney or blocking normal blood flow.

Radiofrequency and ultrasound systems

Modern renal denervation systems primarily use one of two energy sources:

• Radiofrequency energy creates controlled points of heat along the renal artery to interrupt surrounding sympathetic nerves.
• Ultrasound energy delivers circumferential heat into tissue around the artery while using cooling technology to help protect the arterial wall.

The U.S. Food and Drug Administration approved both an ultrasound-based system and a radiofrequency-based system in November 2023. Their approved role is adjunctive: they may help patients whose blood pressure remains inadequately controlled despite lifestyle changes and medication.

How the renal denervation procedure works

Renal denervation is usually performed in a hospital catheterization laboratory by a specially trained interventional physician. The patient receives sedation and pain control. General anesthesia is not always necessary, although local practices and individual needs vary.

1. The physician makes a small puncture, usually in the groin.
2. A thin catheter is inserted into the femoral artery.
3. Using X-ray guidance and contrast dye, the catheter is advanced to the renal arteries.
4. Radiofrequency or ultrasound energy is delivered at carefully selected locations.
5. The catheter is removed, and the access site is closed or compressed.

Treatment is normally performed on arteries supplying both kidneys and often takes about one to two hours. Most patients are monitored for several hours and can go home the same day, although an overnight stay may sometimes be recommended.

Recovery and follow-up

Patients may experience mild groin soreness or bruising. Heavy lifting and strenuous activity are commonly restricted for several days. Follow-up includes checking the access site, kidney function, medications, and blood pressure at home and in the clinic.

The effect is not necessarily immediate. Blood pressure may decline gradually over several weeks or months. Patients should continue all prescribed medicines unless their clinician changes the treatment plan. Retiring the pill organizer without medical approval is not part of the official recovery protocol.

How effective is renal denervation?

Early renal denervation research generated considerable excitement, followed by disappointment when a major sham-controlled trial failed to demonstrate the expected benefit. Researchers then improved catheter designs, procedural techniques, medication monitoring, and trial methods. Newer randomized trials have produced more consistent results.

A 2024 meta-analysis of 10 sham-controlled trials involving 2,478 patients found that renal denervation reduced 24-hour systolic blood pressure by an average of approximately 4.4 mm Hg and office systolic blood pressure by about 6.6 mm Hg compared with a sham procedure. Reductions occurred both in patients taking medication and in those studied without medication.

Depending on the patient, device, and measurement method, the effect is often described as roughly comparable to adding one effective antihypertensive drug. That may sound modest, but blood pressure risk exists on a continuum. Even a sustained reduction of several millimeters of mercury can be clinically valuable across a large population.

A benefit that works throughout the day

Medication concentrations can rise and fall between doses, and missed tablets create additional gaps. Renal denervation works continuously and does not depend on remembering a morning alarm. Ambulatory monitoring suggests that its blood pressure-lowering effect can extend across daytime and nighttime hours.

Clinical studies have demonstrated durability for up to three years in selected groups. Nevertheless, researchers are still collecting longer-term safety and effectiveness data. It is also important to say what has not yet been proved: trials have not established that renal denervation itself directly reduces heart attacks, strokes, kidney failure, or death. Its expected value is based primarily on sustained blood pressure reduction and the well-established relationship between lower blood pressure and lower cardiovascular risk.

Who may be a good candidate?

Renal denervation may be considered for adults with sustained uncontrolled or resistant hypertension after a comprehensive evaluation. Potential candidates include people who:

• Remain above their blood pressure goal while taking several appropriate medications.
• Have difficulty tolerating the medication doses needed for adequate control.
• Have confirmed high readings outside the medical office.
• Have renal arteries suitable for catheter treatment.
• Understand that results vary and medicines may still be required.
• Prefer a procedural option after participating in shared decision-making.

Higher starting blood pressure is currently the most consistent predictor of a larger response. Unfortunately, clinicians cannot guarantee who will respond. Some patients experience a substantial improvement, others see a smaller change, and a minority receive little measurable benefit.

Evaluation before treatment

A qualified hypertension team may review home or 24-hour ambulatory blood pressure readings, medication adherence, kidney function, sleep apnea risk, hormone disorders, and medicines that can raise blood pressure. These may include certain decongestants, stimulants, corticosteroids, nonsteroidal anti-inflammatory drugs, and hormonal treatments.

Imaging is used to examine the renal arteries. Depending on the device and clinical situation, pregnancy, significant renal artery stenosis, aneurysm, fibromuscular dysplasia, a previously stented renal artery, unfavorable artery dimensions, severely impaired kidney function, or inadequate access through the leg arteries may prevent treatment.

Benefits, limitations, and possible risks

The main attraction of renal denervation is straightforward: it is a one-time procedure capable of providing continuous blood pressure reduction without adding another daily tablet. It may also reduce the impact of imperfect medication adherence, a universal human problem that becomes more likely as prescriptions multiply.

Its limitations are equally important. Renal denervation does not address every mechanism responsible for hypertension. It does not eliminate the effects of excess sodium, inactivity, obesity, heavy alcohol use, poor sleep, or untreated sleep apnea. It is not guaranteed to lower blood pressure, and it may not reduce the number of medications a person needs.

Potential complications

Contemporary trials suggest a favorable overall safety profile, with no clear increase in major vascular complications, severe renal artery narrowing, or loss of kidney function compared with sham procedures. However, no invasive procedure is risk-free. Possible complications include:

• Bleeding, bruising, infection, or artery injury at the catheter entry site.
• An allergic reaction or kidney injury related to contrast dye.
• Blood clots or damage to a renal artery.
• Temporary pain or a slowed heart rate during treatment.
• Rare development or worsening of renal artery narrowing.

Careful anatomical screening, experienced operators, and structured follow-up help reduce these risks. The 2025 U.S. hypertension guideline recognizes renal denervation as a possible option for carefully selected patients with resistant or uncontrolled hypertension, emphasizing evaluation by a multidisciplinary team and shared decision-making.

Can renal denervation become a worldwide solution?

Renal denervation could become an important part of global hypertension care, but “worldwide solution” requires a dose of realism. The regions carrying the largest hypertension burden often have limited access to accurate blood pressure measurement, affordable generic medicines, trained specialists, catheterization laboratories, imaging, and follow-up care.

In many communities, the greatest immediate gains will still come from screening, reducing dietary sodium, improving access to validated blood pressure monitors, supplying inexpensive combination medications, and strengthening primary care. A sophisticated procedure cannot compensate for a missing blood pressure cuff or an empty pharmacy shelf.

Where health systems can safely support it, renal denervation may help close a difficult treatment gap. It could be especially valuable for patients with true resistant hypertension, high cardiovascular risk, serious medication intolerance, or persistent adherence barriers. Broader use will depend on cost-effectiveness studies, insurance coverage, specialist training, long-term registries, and equitable distribution of technology.

Questions patients should ask their care team

• Has my hypertension been confirmed with home or ambulatory monitoring?
• Have secondary causes of high blood pressure been evaluated?
• Are my current medications and doses appropriate?
• Is my kidney function adequate, and are my renal arteries suitable?
• Which renal denervation technology would be used, and why?
• How much blood pressure reduction is realistic for me?
• What are the center’s experience and complication rates?
• What costs will my insurance or health system cover?
• How will my blood pressure, kidney function, and medications be monitored afterward?

Conclusion: a promising tool, not a universal cure

Renal denervation has moved from experimental controversy to an FDA-approved treatment supported by modern sham-controlled trials and professional guidance. For an appropriately selected patient, it can provide modest but meaningful, continuous blood pressure reduction with a low rate of serious complications.

Its best role is alongside established hypertension care: accurate measurement, healthy habits, effective medication, and regular follow-up. It should not be presented as kidney surgery, a guaranteed medication replacement, or an instant cure. The most sensible description is simpler: renal denervation is another useful lever clinicians can pull when conventional treatment has not pulled blood pressure down far enough.

What the renal denervation experience may look like

The following examples are educational composite scenarios based on common clinical pathways. They are not testimonials from identifiable patients and do not predict an individual result.

Experience 1: living with a crowded medication schedule

Imagine a 58-year-old office manager whose morning routine includes four blood pressure tablets, a weekly pill organizer, two phone alarms, and the occasional mystery of whether Tuesday’s dose was swallowed or merely considered. Despite months of treatment, home systolic readings frequently remain in the 150s.

Her hypertension specialist first checks her measurement technique, confirms the readings with 24-hour monitoring, and reviews pharmacy records. Testing finds no correctable secondary cause. Because she is taking several appropriate medications and has suitable renal artery anatomy, the team discusses renal denervation.

The procedure takes a little over an hour. She goes home that evening with instructions to protect the groin access site and continue every medication. During the first week, the most noticeable change is mild bruisingnot a dramatic plunge on the monitor. Over the next three months, however, her average readings gradually improve. Her clinician eventually reduces one dose because she develops occasional lightheadedness. The lesson is that success is usually measured through trends and supervised adjustments, not a triumphant disposal of every prescription bottle.

Experience 2: discovering that the procedure is unnecessary

A 66-year-old man is referred after repeated clinic readings near 165/90 mm Hg. He expects to schedule renal denervation immediately. Instead, the specialist orders ambulatory monitoring. Outside the clinic, most readings are considerably lower. His blood pressure rises mainly during medical appointmentsa familiar phenomenon known as white-coat hypertension.

The team improves his home-monitoring plan and adjusts one medication, but does not recommend an invasive procedure. He may feel mildly disappointed after preparing for high-tech treatment, yet avoiding an unnecessary catheter is an excellent outcome. Good patient selection is not a bureaucratic obstacle; it is part of the therapy’s safety.

Experience 3: a modest response that still matters

Consider a 61-year-old teacher with resistant hypertension, sleep apnea, diabetes, and elevated cardiovascular risk. She uses her continuous positive airway pressure device, limits sodium, walks regularly, and takes her medicines consistently. Her average systolic pressure nevertheless remains above goal.

After renal denervation, her systolic pressure falls by approximately 7 mm Hg. She still needs medication, and the change does not feel spectacular from day to day. Yet the reduction is sustained across follow-up measurements, including nighttime readings. For someone already doing the recommended work, a single-digit improvement can represent meaningful added risk reduction. Medical progress does not always arrive with fireworks; sometimes it quietly improves a spreadsheet.

Experience 4: when renal denervation does not deliver the hoped-for result

Another patient completes the procedure safely but sees almost no meaningful change after several months. Repeat monitoring confirms that the lack of response is genuine. His clinicians reassess medication choices, sodium intake, sleep quality, kidney health, and other contributors to hypertension.

This experience can be frustrating because renal denervation cannot currently guarantee a response. It also demonstrates why expectations should be discussed before treatment. A successful procedure means the device was used correctly and safely; it does not automatically mean the patient’s biology will cooperate. Continued hypertension management remains essential whether the response is large, modest, or absent.

Together, these scenarios show that the renal denervation journey begins well before entering the catheterization laboratory. Accurate diagnosis, realistic expectations, experienced care, and months of follow-up are just as important as the energy delivered around the renal arteries.